ContractPurchase Agreement • March 30th, 2022 • BioNTech SE • Biological products, (no disgnostic substances)
ContractAmendment to Letter Agreement • March 30th, 2022 • BioNTech SE • Biological products, (no disgnostic substances)
List of Appendices Appendix 1.1 Patents within the Acuitas LNP Technology as of the License Agreement Effective Date Appendix 1.17 Dual Improvement Patents Appendix 1.23 Jointly Owned Patents Appendix 1.53 Description of the Target(s) Appendix 2.4...Non-Exclusive License Agreement • March 30th, 2022 • BioNTech SE • Biological products, (no disgnostic substances) • England and Wales
Page 2 3. Funding of the Research Program. During the Amendment No. 2 Term, up to ($[***]) of the existing funding for the Original Research Program under the Agreement can be reallocated to fund the Targeting Research Plan upon mutual agreement of...Collaboration & License Agreement • March 30th, 2022 • BioNTech SE • Biological products, (no disgnostic substances)
Appendix 1) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]Lease Agreement • March 30th, 2022 • BioNTech SE • Biological products, (no disgnostic substances)
This Amendment No 6 is made and entered into as of June 01, 2021 ("Amendment No 6 Effective Date") by and between BioNTech SE, a German corporation having its principal office at An der Goldgrube 12, 55131 Mainz, Germany ("Biontech") and Genmab A/S,...License and Collaboration Agreement • March 30th, 2022 • BioNTech SE • Biological products, (no disgnostic substances) • England and Wales
Amended & Restated Development Agreement Execution version 2 1.4 Biontech Co- Development Know-how is defined in Section 4.1.2. 1.5 Biontech Co-Development Patents is defined in Section 4.2.2. 1.6 Biontech Co-Development Technology means the Biontech...Development Agreement • March 30th, 2022 • BioNTech SE • Biological products, (no disgnostic substances)
Legal-47697721/1 162745-0004 2 Execution version – CONFIDENTIAL This Side Letter No 5 is made and entered into as of 12th August 2021 (Side Letter No 5 Effective Date) by and between BioNTech SE, a German corporation having its principal office at An...Side Letter to License and Collaboration Agreement • March 30th, 2022 • BioNTech SE • Biological products, (no disgnostic substances)
